Symbols / ACXP $3.72 +0.95% Acurx Pharmaceuticals, Inc.
ACXP Chart
About
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 10.61M |
| Enterprise Value | 2.95M | Income | -7.97M | Sales | — |
| Book/sh | 2.24 | Cash/sh | 2.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -1.69 | PEG | — |
| P/S | — | P/B | 1.66 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.14 |
| Current Ratio | 3.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.32 | EPS next Y | -2.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -87.60% |
| ROE | -270.80% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.86M |
| Shs Float | 2.73M | Short Float | 38.46% | Short Ratio | 0.14 |
| Short Interest | — | 52W High | 21.00 | 52W Low | 1.33 |
| Beta | -1.92 | Avg Volume | 3.19M | Volume | 7.18K |
| Target Price | $17.00 | Recom | None | Prev Close | $3.68 |
| Price | $3.71 | Change | 0.95% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.00
Mean price target
2. Current target
$3.60
Latest analyst target
3. DCF / Fair value
$-27.06
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.60
Low
$10.00
High
$31.00
Mean
$17.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-08-12 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-19 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-12-15 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-08-15 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-04-11 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2022-12-19 | init | HC Wainwright & Co. | — → Buy | $14 |
| 2022-10-20 | init | Alliance Global Partners | — → Buy | $14 |
- Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance hu, 02 Apr 2026 13
- ACXP Forecast, Price Target & Analyst Ratings | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill hu, 02 Apr 2026 07
- Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate - tipranks.com hu, 12 Mar 2026 07
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Sat, 04 Apr 2026 23
- South Korea grants Acurx patent as it pushes new infection drugs - Stock Titan Mon, 30 Mar 2026 11
- Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year? - Yahoo Finance ue, 17 Mar 2026 07
- ACXP Acurx Pharmaceuticals NASDAQ 10 Mar 2026: Ibezapolstat trial headlines earnings - Meyka ue, 10 Mar 2026 07
- Acurx Pharmaceuticals, Inc. - Common Stock (Nasdaq:ACXP) Stock Quote - FinancialContent Sat, 28 Mar 2026 11
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Sat, 04 Apr 2026 22
- Acurx tests one-drug approach in 20-patient C. diff relapse trial - Stock Titan Mon, 09 Mar 2026 07
- Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance ue, 06 Jan 2026 08
- AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI Sat, 04 Apr 2026 23
- Acurx patent backs new antibiotics for C. diff and MRSA - Stock Titan Mon, 02 Feb 2026 08
- ACXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI Sat, 04 Apr 2026 19
- Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term - Yahoo Finance Wed, 21 Jan 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
8.09
-42.70%
|
14.12
-3.12%
|
14.58
+20.55%
|
12.09
|
| Research And Development |
|
1.83
-66.05%
|
5.40
-10.59%
|
6.04
+27.12%
|
4.75
|
| Selling General And Administration |
|
6.26
-28.23%
|
8.72
+2.17%
|
8.53
+16.29%
|
7.34
|
| General And Administrative Expense |
|
6.26
-28.23%
|
8.72
+2.17%
|
8.53
+16.29%
|
7.34
|
| Other Gand A |
|
6.26
-28.23%
|
8.72
+2.17%
|
8.53
+16.29%
|
7.34
|
| Total Expenses |
|
8.09
-42.70%
|
14.12
-3.12%
|
14.58
+20.55%
|
12.09
|
| Operating Income |
|
-8.09
+42.70%
|
-14.12
+3.12%
|
-14.58
-20.55%
|
-12.09
|
| EBITDA |
|
-8.09
+42.70%
|
-14.12
+3.12%
|
-14.58
-20.55%
|
-12.09
|
| Normalized EBITDA |
|
-8.09
+42.70%
|
-14.12
+3.12%
|
-14.58
-20.55%
|
-12.09
|
| EBIT |
|
-8.09
+42.70%
|
-14.12
+3.12%
|
-14.58
-20.55%
|
-12.09
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Pretax Income |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Net Non Operating Interest Income Expense |
|
0.13
+523.36%
|
0.02
|
—
|
—
|
| Net Interest Income |
|
0.13
+523.36%
|
0.02
|
—
|
—
|
| Interest Income Non Operating |
|
0.13
+523.36%
|
0.02
|
—
|
—
|
| Interest Income |
|
0.13
+523.36%
|
0.02
|
—
|
—
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Net Income From Continuing And Discontinued Operation |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Net Income Continuous Operations |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Normalized Income |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Net Income Common Stockholders |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Diluted EPS |
|
—
|
-17.45
+24.13%
|
-23.00
-2.68%
|
-22.40
|
| Basic EPS |
|
—
|
-17.45
+24.13%
|
-23.00
-2.68%
|
-22.40
|
| Basic Average Shares |
|
—
|
0.81
+27.56%
|
0.63
+17.15%
|
0.54
|
| Diluted Average Shares |
|
—
|
0.81
+27.56%
|
0.63
+17.15%
|
0.54
|
| Diluted NI Availto Com Stockholders |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
7.71
|
| Current Assets |
|
7.71
|
| Cash Cash Equivalents And Short Term Investments |
|
7.47
|
| Cash And Cash Equivalents |
|
7.47
|
| Cash Financial |
|
7.47
|
| Receivables |
|
0.13
|
| Other Receivables |
|
0.13
|
| Prepaid Assets |
|
0.11
|
| Total Non Current Assets |
|
0.00
|
| Total Liabilities Net Minority Interest |
|
3.04
|
| Current Liabilities |
|
3.04
|
| Payables And Accrued Expenses |
|
2.33
|
| Payables |
|
0.00
|
| Other Payable |
|
0.00
|
| Current Accrued Expenses |
|
2.32
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.72
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Stockholders Equity |
|
4.67
|
| Common Stock Equity |
|
4.67
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Share Issued |
|
0.72
|
| Ordinary Shares Number |
|
0.72
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
57.87
|
| Retained Earnings |
|
-53.22
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
4.67
|
| Total Capitalization |
|
4.67
|
| Working Capital |
|
4.67
|
| Invested Capital |
|
4.67
|
| Net Tangible Assets |
|
4.67
|
| Tangible Book Value |
|
4.67
|
| Total Partnership Capital |
|
-53.22
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.79
+34.63%
|
-10.38
-5.94%
|
-9.80
-29.95%
|
-7.54
|
| Cash Flow From Continuing Operating Activities |
|
-6.79
+34.63%
|
-10.38
-5.94%
|
-9.80
-29.95%
|
-7.54
|
| Net Income From Continuing Operations |
|
-7.97
+43.51%
|
-14.10
+3.26%
|
-14.58
-20.55%
|
-12.09
|
| Other Non Cash Items |
|
—
|
—
|
0.56
+29.93%
|
0.43
|
| Pension And Employee Benefit Expense |
|
—
|
—
|
—
|
0.00
|
| Stock Based Compensation |
|
1.57
-54.31%
|
3.44
-8.78%
|
3.77
+14.04%
|
3.30
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-0.39
-237.62%
|
0.28
-71.89%
|
1.01
-19.02%
|
1.25
|
| Change In Receivables |
|
0.00
-96.53%
|
0.08
+160.42%
|
-0.13
|
0.00
|
| Change In Prepaid Assets |
|
0.02
+167.20%
|
0.01
-96.45%
|
0.16
+424.50%
|
0.03
|
| Change In Payables And Accrued Expense |
|
-0.41
-303.98%
|
0.20
-79.57%
|
0.98
-19.46%
|
1.22
|
| Financing Cash Flow |
|
10.64
+60.78%
|
6.62
-18.96%
|
8.16
+120.92%
|
3.70
|
| Cash Flow From Continuing Financing Activities |
|
10.64
+60.78%
|
6.62
-18.96%
|
8.16
+120.92%
|
3.70
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
6.80
+6.09%
|
6.41
+7.76%
|
5.94
+60.86%
|
3.70
|
| Common Stock Payments |
|
-0.00
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-0.00
|
0.00
|
—
|
—
|
| Proceeds From Stock Option Exercised |
|
3.84
+1727.36%
|
0.21
-90.53%
|
2.22
+17069684.62%
|
0.00
|
| Changes In Cash |
|
3.85
+202.17%
|
-3.77
-130.07%
|
-1.64
+57.43%
|
-3.85
|
| Beginning Cash Position |
|
3.71
-50.41%
|
7.47
-17.97%
|
9.11
-29.69%
|
12.96
|
| End Cash Position |
|
7.56
+103.85%
|
3.71
-50.41%
|
7.47
-17.97%
|
9.11
|
| Free Cash Flow |
|
-6.79
+34.63%
|
-10.38
-5.94%
|
-9.80
-29.95%
|
-7.54
|
| Common Stock Issuance |
|
6.80
+6.11%
|
6.41
+7.76%
|
5.94
+60.86%
|
3.70
|
| Issuance Of Capital Stock |
|
6.80
+6.11%
|
6.41
+7.76%
|
5.94
+60.86%
|
3.70
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-12 View
- 8-K2026-03-09 View
- 10-Q2025-11-12 View
- 8-K2025-09-22 View
- 8-K2025-09-19 View
- 10-Q2025-08-11 View
- 8-K2025-07-31 View
- 8-K2025-07-17 View
- 8-K2025-06-20 View
- 8-K2025-05-13 View
- 10-Q2025-05-12 View
- 8-K2025-05-08 View
- 8-K2025-03-28 View
- 8-K2025-03-18 View
- 10-K2025-03-17 View
- 8-K2025-03-10 View
- 8-K2025-02-26 View
- 42025-02-06 View
- 42025-02-06 View
- 42025-02-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|